Dihydro-β-erythroidine (hydrobromide)

Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active, and competitive antagonist of neuronal nAChRs. Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC50s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities[1][2][3].

Product Specifications

CAS Number

[29734-68-7]

Product Name Alternative

DHβE (hydrobromide)

UNSPSC

12352005

Target

NAChR

Type

Natural Products

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/dihydro-β-erythroidine-hydrobromide.html

Purity

98.85

Solubility

DMSO : 8 mg/mL (ultrasonic; warming) |H2O : ≥ 100 mg/mL

Smiles

CO[C@@H]1C[C@]23C(CC4=O)=C(CO4)CCN2CCC3=CC1.Br

Molecular Formula

C16H22BrNO3

Molecular Weight

356.25

References & Citations

[1]Harvey SC, et al. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J Neurochem. 1996 Nov;67 (5) :1953-9.|[2]Tabbara RI, et al. Nicotine enhances responding for conditioned reinforcement via α4β2 nicotinic acetylcholine receptors in the ventral tegmental area, but not the nucleus accumbens or the prefrontal cortex. Neuropharmacology. 2019 Apr;148:68-76.|[3]Clementson S, et al. Enantioselective Total Synthesis of (+) -Dihydro-β-erythroidine. J Am Chem Soc. 2019 Jun 5;141 (22) :8783-8786.